PureTech Share News (PRTC)

IN BRIEF: PureTech's LYT-100 shows 50% improvement to key adverse events

PureTech Health PLC - Boston-based biotechnology company - Says LYT-100 trial shows around 50% improvement in gastrointestinal and central nervous system related adverse events in adults suffering from idiopathic pulmonary fibrosis compared to US Food & Drug Administration-approved pirfenidone. Adds data shows higher dose of LYT-100 well-tolerated with no additional incidence of GI or CNS AEs when titrated up from 550 milligrams dosage.

PureTech Health subsidiary receives fast track designation for VE202

(Alliance News) - PureTech Health PLC on Wednesday said its subsidiary Vedanta Biosciences has received fast-track designation for its VE202 treatment.

TRADING UPDATES: Rockhopper loss widens; Synectics inks new contract

(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Arix Bioscience boosts net value, CEO jumping ship for PureTech Health

(Alliance News) - Arix Bioscience PLC on Wednesday said net asset value increased in its latest half year, but has since launched a strategic review due to "unfavourable" conditions while Chief Executive Officer Robert Lyne prepares to step down.

PureTech narrows interim loss despite "stormy market challenges"

(Alliance News) - PureTech Health PLC on Tuesday said its half-year loss narrowed, but saw its revenue fall by more than half.

LONDON MARKET OPEN: FTSE 100 catches up with bank holiday rally

(Alliance News) - Stock prices in London opened higher on Tuesday, as UK markets return from a long bank holiday weekend and news that UK shop price inflation decelerated in August.

LONDON BRIEFING: Bunzl profit up; Rio Tinto sells copper project stake

(Alliance News) - Stocks in London are called to open higher on Tuesday, following a long bank holiday weekend.

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Plant Health in Poland boost; PureTech gets US grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

PureTech Health launches next stage of anxiety disorder drug trial

(Alliance News) - PureTech Health PLC on Wednesday said that it has started the next stage of trials for LYT-300, in order to test whether the therapy could be used to treat anxiety disorders.

PureTech Health's Akili launches ADHD immersive treatment in US

(Alliance News) - PureTech Health PLC on Wednesday said its founded entity, Akili Inc, released an attention deficit hyperactivity disorder treatment for adult patients.

PureTech's Vedanta Biosciences receives US FDA fast track designation

(Alliance News) - PureTech Health PLC on Tuesday said its founded entity, Vedanta Biosciences, has been granted fast track designation from the US Food & Drug Administration for its bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection.

IN BRIEF: PureTech notes Akili's results for EndeavorRx ADHD trial

PureTech Health PLC - Boston-based biotechnology company - Says its founded entity, Akili, announced clinical trial for video game-based therapy, EndeavorRx, showed improvement in attention and quality of life for people with attention deficit hyperactivity disorder. Notes attention improved in more than 80% of adults with ADHD, while over a third of participants "no longer exhibited an attention deficit following treatment."

LONDON BROKER RATINGS: HSBC raises Rightmove to 'buy' from 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

PureTech Health yearly loss widens but remains optimistic

(Alliance News) - PureTech Health PLC on Friday said its loss widened in 2022 and revenue declined, though it hailed an "exceptional" year and expects further success in 2023.